Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hepatitis b: experimental drug shows promise in mid-stage trial

NCT ID NCT04412863

Disease control Sponsor: Vir Biotechnology, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called VIR-2218 in 84 adults with chronic hepatitis B. Some participants received VIR-2218 alone, and others got it combined with pegylated interferon. The main goals were to check safety and how well the drug works against the virus. The study is complete, and results will help decide if further testing is needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

84 people

The number who actually took part.

Started

Jul 2020

Finished

Mar 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female of ages 18 - 65 * Chronic HBV infection for \>/= 6 months Exclusion Criteria: * Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation * Significant fibrosis or cirrhosis * History or evidence of drug or alcohol abuse * History of intolerance to SC injection * History of chronic liver disease from any cause other than chronic HBV infection * History of hepatic decompensation * Any prior receipt of an interferon product

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hepatitis B are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic hepatitis B

Contacts and locations

Locations

  • Investigative Site

    Birtinya, Queensland, 4575, Australia

  • Investigative Site

    Fitzroy, Victoria, 3168, Australia

  • Investigative Site

    Batu Caves, 68100, Malaysia

  • Investigative Site

    Kajang, 43000, Malaysia

  • Investigative Site

    Kuala Lumpur, 59100, Malaysia

  • Investigative Site

    Kuantan, 25100, Malaysia

  • Investigative Site

    Auckland, 1010, New Zealand

  • Investigative Site

    Auckland, 2025, New Zealand

  • Investigative Site

    Busan, 49241, South Korea

  • Investigative Site

    Chuncheon, 24253, South Korea

  • Investigative Site

    Daegu, 41944, South Korea

  • Investigative Site

    Seoul, 03080, South Korea

  • Investigative Site

    Seoul, 05505, South Korea

  • Investigative Site

    Yangsan, 50612, South Korea

  • Investigative Site

    Bangkok, 10330, Thailand

  • Investigative Site

    Bangkok, 10400, Thailand

  • Investigative Site

    Bangkok, 10700, Thailand

  • Investigative Site

    Chiang Mai, 50200, Thailand

  • Investigative Site

    Hat Yai, 90110, Thailand

  • Investigative Site

    Khlong Luang, 12120, Thailand

  • Investigative Site

    Khon Kaen, 40002, Thailand

  • Investigative site

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.